Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Capital Expenditures (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Capital Expenditures data on record, last reported at $78000.0 in Q2 2025.

  • For Q2 2025, Capital Expenditures changed N/A year-over-year to $78000.0; the TTM value through Dec 2025 reached $686000.0, up 379.72%, while the annual FY2025 figure was $686000.0, 379.72% up from the prior year.
  • Capital Expenditures reached $78000.0 in Q2 2025 per ARQT's latest filing, down from $608000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $608000.0 in Q1 2025 and bottomed at $6000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $172333.3, with a median of $123000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 1251.22% in 2021, then tumbled 95.62% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $261000.0 in 2021, then plummeted by 52.87% to $123000.0 in 2022, then tumbled by 95.12% to $6000.0 in 2023, then soared by 2283.33% to $143000.0 in 2024, then plummeted by 45.45% to $78000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $78000.0 in Q2 2025, $608000.0 in Q1 2025, and $143000.0 in Q3 2024.